Physician profile
Sonali Hanson
NPI 1518932755
$3,276.91
in general payments reported to CMS, 2019-2025
20 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $11.67 · 2021: $266 · 2022: $627 · 2023: $389 · 2024: $512 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $592.06 | 2019-2025 | |
| Genzyme Corporation | $589.33 | 2022-2025 | |
| Pfizer INC. | $431.60 | 2019-2025 | |
| Abbvie INC. | $352.86 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $215.86 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $193.96 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $152.62 | 2022-2024 | Vtama |
| Incyte Corporation | $148.95 | 2021-2025 | Opzelura |
| Revance Therapeutics, INC. | $125.07 | 2025 | Daxxify |
| Organon LLC | $108.03 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $92.02 | 2022-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $73.05 | 2022-2025 | Nemluvio |
| Ucb, INC. | $55.30 | 2022-2025 | Bimzelx |
| Botanix Sb INC | $37.26 | 2025 | Sofdra |
| Biocon Biologics INC | $23.43 | 2025 | Hulio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $21.45 | 2019 | |
| Lilly USA, LLC | $19.40 | 2022 | |
| Sanofi US Services INC. | $17.57 | 2024 | |
| Leo Pharma INC. | $14.31 | 2025 | Anzupgo |
| Krystal Biotech INC | $12.78 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.